- Product Details
Keywords
- Tigecycline manufacture
- Tigecycline buy
- Tigecycline high quality
Quick Details
- ProName: Tigecycline
- CasNo: 220620-09-7
- Appearance: Orange crystalline powder
- Application: glycylcycline antibiotic
- DeliveryTime: within 1-7 days after your payment
- PackAge: aluminum foil bag or customized
- Port: Shanghai
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99%
- Storage: cool.sealed place
- Transportation: by courier or as your request
- LimitNum: 1 Kilogram
Superiority
We could give you:
1. Best quality in your requirement
2. Competitive price in China market
3. Mature Technical support
4. Professional logistic support
Details
Name: Tigecycline
Protein binding:71-89%
Metabolism:not metabolised
Half-life:42.4 hours
Excretion:59% biliary, 33% renal
CAS number:220620-09-7
ChemSpider:10482314
UNII:70JE2N95KR
KEGG:D01079
Formula:C29H39N5O8
Mol. mass:585.65 g/mol
Synonyms:N-[(5aR,6aS,7S,9Z,10aS)-9-(amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide
IUPAC:N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5,5a,6,6a,7,8,9,10,10a,11-decahydrotetracen-2-yl]-2-(tert-butylamino)acetamide
Product information:
Tigecycline is the first drug in the glycylcycline class of antibiotics. Although it is structurally related to minocycline, alterations to the molecule resulted in its expanded spectrum of activity and decreased susceptibility to the development of resistance when compared with other tetracycline antibiotics. Tigecycline has a broad spectrum of activity, including activity against drug-resistant gram-positive organisms. Randomized trials have shown tigecycline to be efficacious for the treatment of complicated intraabdominal infections and complicated skin and skin structure infections. The dose of tigecycline is 50 mg intravenously every 12 hours after a 100-mg loading dose. Nausea, vomiting, and diarrhea were the most common adverse events reported with tigecycline therapy and may result in discontinuation of therapy.